Pfizer Inc. (PFE): Price and Financial Metrics

PFE POWR Grades

• Value is the dimension where PFE ranks best; there it ranks ahead of 92.77% of US stocks.
• The strongest trend for PFE is in Momentum, which has been heading down over the past 179 days.
• PFE's current lowest rank is in the Momentum metric (where it is better than 8.18% of US stocks).

PFE Stock Summary

• PFE has a higher market value than 99.48% of US stocks; more precisely, its current market capitalization is $296,575,292,881.
• Pfizer Inc's stock had its IPO on January 1, 1986, making it an older stock than 92.84% of US equities in our set.
• As for revenue growth, note that PFE's revenue has grown 93.97% over the past 12 months; that beats the revenue growth of 91.33% of US companies in our set.
• Stocks that are quantitatively similar to PFE, based on their financial statements, market capitalization, and price volatility, are LLY, ABBV, MRK, ASML, and INTC.
• PFE's SEC filings can be seen here. And to visit Pfizer Inc's official web site, go to www.pfizer.com.

PFE Valuation Summary

• PFE's price/sales ratio is 5; this is 55.95% lower than that of the median Healthcare stock.
• PFE's price/sales ratio has moved down 2.9 over the prior 243 months.
• Over the past 243 months, PFE's price/earnings ratio has gone down 17.6.

Below are key valuation metrics over time for PFE.

PFE Growth Metrics

The 2 year net income to common stockholders growth rate now stands at -27.39%.
• The 2 year cash and equivalents growth rate now stands at -6.56%.
• Its 5 year net cashflow from operations growth rate is now at -9.4%.

Over the past 34 months, PFE's revenue has gone up $27,429,000,000.

The table below shows PFE's growth in key financial areas (numbers in millions of US dollars).

Date	Revenue	Operating Cash Flow	Net Income to Common Stock
2021-12-31	81,288	32,580	21,979
2021-09-30	63,600	32,291	19,180
2021-06-30	51,637	23,552	13,228
2021-03-31	44,461	15,808	11,091
2020-12-31	41,908	14,403	9,616
2020-09-30	48,648	12,547	8,685

PFE's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.

• PFE has a Quality Grade of B, ranking ahead of 88% of graded US stocks.
• PFE's asset turnover comes in at 0.312 -- ranking 146th of 682 Pharmaceutical Products stocks.
• XBIT, NERV, and BLUE are the stocks whose asset turnover ratios are most correlated with PFE.

The table below shows PFE's key quality metrics over time.